Resveratrol: the longevity molecule that didn't survive contact with humans

Resveratrol is the most instructive failure in the longevity supplement world, and understanding why it failed teaches you how to read every other entry in this guide with the right amount of skepticism. It’s the compound behind the phrase “a glass of red wine is good for you,” behind the sirtuin gold rush of the 2000s, and behind a supplement category that still sells briskly two decades after the science underneath it started falling apart. The short version: the mechanism was oversold, the drug barely gets into you, and it doesn’t work in people.

That’s a strong claim, so here’s the evidence, in the order the story actually unfolded.

The sirtuin story, and how it cracked

In 2003, a high-profile screen reported that resveratrol activates SIRT1 — a sirtuin enzyme linked to the longevity benefits of caloric restriction — and extends lifespan in yeast. The narrative was irresistible: a molecule in red wine that flips the same switch as eating less, without eating less. It launched a company (Sirtris), a $720 million acquisition by GlaxoSmithKline in 2008, and a thousand supplement labels promising to “activate your sirtuins.”

Then independent labs looked closer. By 2010, work by Pacholec and colleagues showed that resveratrol and related “sirtuin-activating compounds” were not direct activators of SIRT1 — the apparent activation in the original assay was an artifact of the fluorescent tag on the peptide substrate used in the test. The compounds interacted with the fluorophore, not with the enzyme working on its real targets. GSK ultimately shuttered the Sirtris labs in 2013. The mechanism didn’t vanish entirely — there’s an ongoing, genuinely technical debate about substrate-dependent effects — but the clean “resveratrol presses the SIRT1 gas pedal” story that sold the supplements did not hold up.

The bioavailability problem

Even if you set the mechanism aside, there’s a plumbing problem. Resveratrol is well-absorbed but has very low oral bioavailability — it’s rapidly metabolized in the gut and liver, so the amount that reaches your tissues in active form after swallowing a capsule is tiny. Many of the striking effects reported in cell culture used concentrations you essentially cannot achieve by eating or supplementing. That gap alone should make anyone cautious about extrapolating from a petri dish to a person.

What human trials actually show

The human data are the quiet part the marketing skips. There is no human trial showing resveratrol extends lifespan or healthspan. Trials on surrogate endpoints — glucose metabolism, vascular function, inflammation — have been heterogeneous and frequently null, with effects that appear in one study and disappear in the next. Observational work has been similarly deflating: a well-known cohort study measuring urinary resveratrol metabolites in older adults found no association with inflammation, cardiovascular disease, cancer, or all-cause mortality. And the celebrated mouse result — resveratrol improving survival — was seen mainly in overfed, obese mice, not healthy ones, meaning even the animal data were narrower than the headlines implied.

The honest bottom line

Resveratrol is cheap and low-risk, so nobody’s health is in danger from a bottle of it. But “low-risk” is not a reason to take something; evidence of benefit is, and here there isn’t any for longevity. Its foundational mechanism was largely an assay artifact, it barely reaches your tissues, and human outcomes are null. Skip it.

Keep the story, though. Resveratrol is the cleanest example of why this guide grades animal and mechanistic evidence so far below human trials: a beautiful hypothesis, a huge acquisition, an entire supplement aisle — and, when the rigorous human data finally came in, essentially nothing. When you see the next “yeast-to-mice-to-you” longevity molecule, remember how this one ended.